ClinicalTrials.gg
Active, not recruitingNCT06104943STRIREGUpdated Oct 27, 2023

Stockholm hyperTRIglyceridemia REGister (STRIREG) Study

An observational study in Familial Hypertriglyceridemia, sponsored by Region Stockholm. Active, not recruiting. Per ClinicalTrials.gov, last updated 2023-10-27.

Sponsored by Region Stockholm · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
3,607,819
Sex
All
01

Study summary

The STRIREG study is a retrospective longitudinal general population-based register study including all individuals who had had at least one plasma Tg measurement between 1st January 2000 and 31st December 2021 at Karolinska University Laboratory or Unilabs AB in Region Stockholm (population 2.41 million 2021). The exclusion criteria were a lack of a unique Swedish personal identification number (PIN). The index population consisted of 1,460,184 individuals between the age 0 and 107 years. The index population was extended to form the complete cohort (n=3,607,819) by associating the parents and the siblings (n=2,147,635) to the indexes by interlinkage of personal identification numbers via the Multi-Generation register (see below).

The study baseline for the index population was defined as the date for participant's first Tg measurement.

Read the detailed description

Hypertriglyceridemia (hTG) is associated with atherosclerotic cardiovascular disease, pancreatitis, and non-alcoholic fatty liver disease in large population-based studies. Less is known about the impact on hereditary hTG and cardiometabolic disease status for the development of hTG and its associated cardiometabolic outcomes. hTG remains a target for lipid lowering therapies and with new pharmacological interventions being developed, there is a need to identify patients that will benefit most from treatment with these new medicines.

The population-based observational Stockholm hyperTRIglyceridemia REGister (STRIREG) study include 1,460,184 index individuals that have measured plasma triglycerides in the clinical routine in Region Stockholm, Sweden, between 1st January 2000 and 31st December 2021. The laboratory measurements also included basic haematology, blood lipid panel, liver function tests and HbA1c. Using the Swedish Multi-Generation register, 2,147,635 parents and siblings to the indexes were identified to form the complete study cohort. Laboratory data from participants were combined with data from several national registers that provided information on cause of death, medical diagnoses, dispensed medicines, and socioeconomic factors including country of birth, education level and marital status.

The multigenerational longitudinal STRIREG cohort provides a unique opportunity to investigate different aspects of familial hTG as well as heredity for other metabolic diseases. Important outcome measures include mortality, cardiovascular mortality, major cardiovascular events, development of incident diabetes, and non-alcoholic fatty liver disease. The STRIREG study will provide a deeper understanding of the impact of heredity on hTG and associated cardiometabolic complications.

02

Conditions studied

  • Familial Hypertriglyceridemia
03

In context

Lead sponsor

Region Stockholm is the lead sponsor of 122 studies on the registry; 70 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Populationbased cohort originating from Stockholm County. with all individuals who had had at least one plasma Triglyceride measurement between 1st January 2000 and 31st December 2021 at Karolinska University Laboratory or Unilabs AB in Stockholm County Sweden. The first degree relatives are parents and siblings to the index patients identified through the Swedish Multi-Generation Register.

Eligibility criteria

Inclusion Criteria: All individuals who had had at least one plasma Triglyceride measurement between 1st January 2000 and 31st December 2021 at Karolinska University Laboratory or Unilabs AB in Stockholm County Sweden.

Exclusion Criteria: No Swedish social security number.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
3,607,819 participants (actual)
Target follow-up
21 Years
Patient registry
Yes

Groups and cohorts

  • Index patients

    All individuals who had had at least one plasma Triglyceride measurement between 1st January 2000 and 31st December 2021 at Karolinska University Laboratory or Unilabs AB in Stockholm County in Sweden.

    Other: Heredity for cardiovascular disease · Other: Heredity for pancreatitis · Other: Heredity for type 2 diabetes · Other: Heredity for hypertriglyceridemia

  • First degree relatives to index patients

    Parents and the siblings to the index patients by interlinkage of personal identification numbers via the Swedish Multi-Generation register.

Interventions

  • OtherHeredity for cardiovascular disease

    First degree relatives with a diagnosis of Cardiovascular disease.

  • OtherHeredity for pancreatitis

    First degree relatives with a diagnosis of pancreatitis.

  • OtherHeredity for type 2 diabetes

    First degree relatives with a diagnosis of type 2 diabetes.

  • OtherHeredity for hypertriglyceridemia

    First degree relatives with hypertriglyceridemia

06

What researchers measure

Primary outcomes

  1. Mortality

    All cause mortality

    Time frame: Jan 1 2000 to Dec 31 2021

  2. Cardiovascular mortality

    Cardiovascular mortality

    Time frame: Jan 1 2000 to Dec 31 2021

  3. Pancreatitis

    Pancreatitis

    Time frame: Jan 1 2000 to Dec 31 2021

  4. Major cardiovascular event (MACE)

    Major cardiovascular event (MACE)

    Time frame: Jan 1 2000 to Dec 31 2021

Secondary outcomes

  1. Myocardial infarction

    Myocardial infarction

    Time frame: Jan 1 2000 to Dec 31 2021

  2. Stroke

    Stroke

    Time frame: Jan 1 2000 to Dec 31 2021

  3. Peripheral artery disease

    Peripheral artery disease

    Time frame: Jan 1 2000 to Dec 31 2021

  4. Type 2 diabetes

    Type 2 diabetes

    Time frame: Jan 1 2000 to Dec 31 2021

  5. Cardiac revascularization

    Cardiac revascularization

    Time frame: Jan 1 2000 to Dec 31 2021

  6. Non alcoholic fatty liver disease

    Non alcoholic fatty liver disease

    Time frame: Jan 1 2000 to Dec 31 2021

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2000 to primary completion in Dec 2021, 263 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 23, 2023
First posted
Oct 27, 2023
StartActual
Jan 1, 2000
Primary completionActual
Dec 31, 2021
CompletionEst.
Dec 31, 2027
Last update
Oct 27, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 27, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06104943
Lead sponsor
Region Stockholm
Responsible party
Sponsor
First posted
Oct 27, 2023
Start date
Jan 1, 2000
Primary completion
Dec 31, 2021
Completion
Dec 31, 2027 (estimated)
Last update
Oct 27, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion